File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Neurocognitive evaluation and plasma clozapine concentrations in Chinese patients with treatment-refractory schizophrenia

TitleNeurocognitive evaluation and plasma clozapine concentrations in Chinese patients with treatment-refractory schizophrenia
Authors
Issue Date2002
PublisherCambridge University Press. The Journal's web site is located at http://journals.cambridge.org/action/displayJournal?jid=PNP
Citation
The 23rd CINP Congress, Montréal, Canada, 23-27 June 2002. In International Journal of Neuropsychopharmacology, 2002, v. 5 n. suppl, p. 127, abstarct P.2.W.041 How to Cite?
AbstractClozapine has been shown to be effective in treatment-refractory schizophrenia for positive and negative symptoms as well as some neurocognitive dysfunction. Nineteen patients with treatment-refractory schizophrenia were recruited for a 3-month trial of clozapine. Clozapine was titrated against clinical response to a maximum daily dosage of 200mg, 400mg and 600mg in the first, second and third month respectively. Steady-state blood concentrations of clozapine, clozapine-Noxide and N-desmethylclozapine were determined at the end of each month. At baseline and the end of each month, patients were assessed by using Positive and Negative Syndrome Scales, High Royds Evaluation of Negativity, Montgomery-Asberg Depression Rating Scale and Clinical Global Impression(severity & change) for their clinical symptoms and Abnormal Involuntary Movement Scale, Simpson-Angus Scale and Barnes Akathisia Rating Scale for the extra-pyramidal side effects. Neurocognitive function was assessed by applying Wisconsin card sorting, verbal fluency, digit spans, logical memory, visual memory, Stroop test, continuous performance test and Cambridge neurological inventory at baseline and at the end of the third month. Our results showed that 55.6% of the subjects responded at the end of the 3-month trial. The responders showed significant improvement in immediate and delayed logical memory and a trend of better performance in Stroop test at the end of the trial. The mean daily dosage for responder was 442.5mg (sd: 40.8) with blood concentration at 786.1 ng/ml (sd:118.2), 104.7 ng/ml (sd:12.0) and 570.1 ng/ml (sd:95.0) for clozapine, clozapine-N-oxide and N-desmethylclozapine respectively. The blood concentrations did not predicit clinical response. In conclusions, our study provides evidence for clinical efficacy of clozapine not only on psychopathology but also on memory and selective attention.
DescriptionThis journal suppl. entitled: Abstracts from the XXIII CINP Congress, Montréal, June 23–27, 2002
Persistent Identifierhttp://hdl.handle.net/10722/105335
ISSN
2015 Impact Factor: 4.333
2015 SCImago Journal Rankings: 1.690

 

DC FieldValueLanguage
dc.contributor.authorChen, RYLen_HK
dc.contributor.authorSiu, TSen_HK
dc.contributor.authorTam, Sen_HK
dc.contributor.authorChen, EYHen_HK
dc.date.accessioned2010-09-25T22:29:52Z-
dc.date.available2010-09-25T22:29:52Z-
dc.date.issued2002en_HK
dc.identifier.citationThe 23rd CINP Congress, Montréal, Canada, 23-27 June 2002. In International Journal of Neuropsychopharmacology, 2002, v. 5 n. suppl, p. 127, abstarct P.2.W.041en_HK
dc.identifier.issn1461-1457en_HK
dc.identifier.urihttp://hdl.handle.net/10722/105335-
dc.descriptionThis journal suppl. entitled: Abstracts from the XXIII CINP Congress, Montréal, June 23–27, 2002-
dc.description.abstractClozapine has been shown to be effective in treatment-refractory schizophrenia for positive and negative symptoms as well as some neurocognitive dysfunction. Nineteen patients with treatment-refractory schizophrenia were recruited for a 3-month trial of clozapine. Clozapine was titrated against clinical response to a maximum daily dosage of 200mg, 400mg and 600mg in the first, second and third month respectively. Steady-state blood concentrations of clozapine, clozapine-Noxide and N-desmethylclozapine were determined at the end of each month. At baseline and the end of each month, patients were assessed by using Positive and Negative Syndrome Scales, High Royds Evaluation of Negativity, Montgomery-Asberg Depression Rating Scale and Clinical Global Impression(severity & change) for their clinical symptoms and Abnormal Involuntary Movement Scale, Simpson-Angus Scale and Barnes Akathisia Rating Scale for the extra-pyramidal side effects. Neurocognitive function was assessed by applying Wisconsin card sorting, verbal fluency, digit spans, logical memory, visual memory, Stroop test, continuous performance test and Cambridge neurological inventory at baseline and at the end of the third month. Our results showed that 55.6% of the subjects responded at the end of the 3-month trial. The responders showed significant improvement in immediate and delayed logical memory and a trend of better performance in Stroop test at the end of the trial. The mean daily dosage for responder was 442.5mg (sd: 40.8) with blood concentration at 786.1 ng/ml (sd:118.2), 104.7 ng/ml (sd:12.0) and 570.1 ng/ml (sd:95.0) for clozapine, clozapine-N-oxide and N-desmethylclozapine respectively. The blood concentrations did not predicit clinical response. In conclusions, our study provides evidence for clinical efficacy of clozapine not only on psychopathology but also on memory and selective attention.-
dc.languageengen_HK
dc.publisherCambridge University Press. The Journal's web site is located at http://journals.cambridge.org/action/displayJournal?jid=PNPen_HK
dc.relation.ispartofInternational Journal of Neuropsychopharmacologyen_HK
dc.rightsInternational Journal of Neuropsychopharmacology. Copyright © Cambridge University Press.en_HK
dc.titleNeurocognitive evaluation and plasma clozapine concentrations in Chinese patients with treatment-refractory schizophreniaen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1461-1457&volume=5 &issue=suppl&spage=127&epage=&date=2002&atitle=Neurocognitive+evaluation+and+plasma+clozapine+concentrations+in+Chinese+patients+with+treatment-refractory+schizophreniaen_HK
dc.identifier.emailChen, RYL: rylchen@hkucc.hku.hken_HK
dc.identifier.emailChen, EYH: eyhchen@hku.hken_HK
dc.identifier.doi10.1017/S1461145702003176-
dc.identifier.hkuros82820en_HK
dc.identifier.volume5en_HK
dc.identifier.issuesupplen_HK
dc.identifier.spage127, abstarct P.2.W.041en_HK
dc.identifier.epage127, abstarct P.2.W.041-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats